Cimetropium: characterization of antimuscarinic and spasmolytic properties
- PMID: 4026901
Cimetropium: characterization of antimuscarinic and spasmolytic properties
Abstract
Cimetropium displaced 3H-NMS binding from membranes derived from gastrointestinal smooth muscle. The affinity of cimetropium for intestinal muscarinic receptors was in the range 70-100 nM. The competitive antagonism of cimetropium was demonstrated in guinea-pig ileum and taenia coli stimulated by bethanechol. Comparing pA2 values, cimetropium (8.19 and 7.91, resp.) was 0.3 times as potent as atropine (8.52 and 8.41, resp.). Cimetropium displayed strong inhibitory effects towards BaCl2 and 5-hydroxytryptamine induced contractions of the guinea-pig ileum. The compound was devoid of antihistaminic or Ca++ channel blocking activity. A binding study performed in vivo confirmed the ability of i.v. cimetropium to displace 3H-N-methylscopolamine binding from muscarinic receptors in peripheral organs. In addition, when injected into ileal loops, cimetropium displaced 3H-NMS binding solely from the surrounding tissue of the loop, indicating a topical effect of the compound.
Similar articles
-
Effect of cimetropium bromide and other antispasmodic compounds on in vitro guinea-pig gallbladder.Methods Find Exp Clin Pharmacol. 1989 May;11(5):323-9. Methods Find Exp Clin Pharmacol. 1989. PMID: 2755278
-
New classes of antimuscarinic agents endowed with selective antispasmodic properties. 1-Arylsulfonyl pyrrolidin-2-ones and 2-thiones, 1-arylsulfonyl piperidin-2-ones and 2-thiones and 1-arylsulfonyl hexahydro-2H-azepin-2-one.Arzneimittelforschung. 1994 Apr;44(4):501-9. Arzneimittelforschung. 1994. PMID: 8011004
-
Increased muscarinic responsiveness and decreased muscarinic receptor content in ileal smooth muscle in diabetes.J Pharmacol Exp Ther. 1990 Aug;254(2):445-9. J Pharmacol Exp Ther. 1990. PMID: 2384882
-
Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives.Int J Clin Pharmacol Res. 1985;5(6):467-77. Int J Clin Pharmacol Res. 1985. PMID: 3912339 Review.
-
Pharmacological studies on otilonium bromide.Ital J Gastroenterol. 1991 Nov;23(8 Suppl 1):56-9. Ital J Gastroenterol. 1991. PMID: 1661629 Review.
Cited by
-
Urinary excretion of cimetropium bromide after multiple oral doses.Eur J Clin Pharmacol. 1987;33(3):337-8. doi: 10.1007/BF00637575. Eur J Clin Pharmacol. 1987. PMID: 3691626 No abstract available.
-
Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.Gut. 1990 Mar;31(3):355-8. doi: 10.1136/gut.31.3.355. Gut. 1990. PMID: 2182401 Free PMC article. Clinical Trial.
-
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.Eur J Clin Pharmacol. 1988;33(6):571-5. doi: 10.1007/BF00542489. Eur J Clin Pharmacol. 1988. PMID: 3366160 Clinical Trial.
-
Incidence of propofol injection pain and effect of lidocaine pretreatment during upper gastrointestinal endoscopy.Dig Dis Sci. 2012 May;57(5):1291-7. doi: 10.1007/s10620-011-1992-4. Epub 2011 Dec 13. Dig Dis Sci. 2012. PMID: 22160549 Clinical Trial.
-
Effect of cimetropium bromide on esophageal motility and transit in patients affected by primary achalasia.Dig Dis Sci. 1994 Jul;39(7):1389-94. doi: 10.1007/BF02088038. Dig Dis Sci. 1994. PMID: 8026247 Clinical Trial.